Edwards Lifesciences Corporation (EW) : Traders are bullish on Edwards Lifesciences Corporation (EW) as it has outperformed the S&P 500 by a wide margin of 4.63% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.49%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.66% in the last 1 week, and is up 4.07% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 2.59% and the 50-Day Moving Average is 4.8%.The 200 Day SMA reached 22.5%
Edwards Lifesciences Corporation (NYSE:EW): After opening at $119.66, the stock dipped to an intraday low of $119.45 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $121.08 and the buying power remained strong till the end. The stock closed at $120.56 for the day, a gain of 1.09% for the day session. The total traded volume was 999,053. The stocks close on the previous trading day was $120.56.
Edwards Lifesciences Corporation (EW) : The highest level Edwards Lifesciences Corporation (EW) is projected to reach is $140 for the short term and the lowest estimate is at $105. The consolidated price target from 14 rating analysts who initiate coverage on the stock is $126.36 and the possibility the share price can swing is $10.13.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.